![](/images/graphics-bg.png)
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
Joint Authors
Komatsu, Nobukazu
Sasada, Tetsuro
Yamada, Akira
Ueshima, Kazuomi
Abe, Kazumichi
Ishiguro, Atsushi
Eguchi, Junichi
Shichijo, Shigeki
Noguchi, Masanori
Kudo, Masatoshi
Yutani, Shigeru
Itoh, Kyogo
Matsueda, Satoko
Source
Journal of Immunology Research
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-10-11
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Objective.
To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC).
Patients and Methods.
Patients diagnosed with HCV-positive advanced HCC were eligible for this study.
A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35–44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks.
Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination.
Results.
Forty-two patients were enrolled.
Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted.
Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination.
Peptide-specific IgG responses were also boosted in 19 of 36 patients.
Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival.
Conclusion.
Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction.
American Psychological Association (APA)
Yutani, Shigeru& Ueshima, Kazuomi& Abe, Kazumichi& Ishiguro, Atsushi& Eguchi, Junichi& Matsueda, Satoko…[et al.]. 2015. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. Journal of Immunology Research،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1068485
Modern Language Association (MLA)
Yutani, Shigeru…[et al.]. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. Journal of Immunology Research No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1068485
American Medical Association (AMA)
Yutani, Shigeru& Ueshima, Kazuomi& Abe, Kazumichi& Ishiguro, Atsushi& Eguchi, Junichi& Matsueda, Satoko…[et al.]. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. Journal of Immunology Research. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1068485
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1068485